[en] Adiponectin, cytokine produced by differentiated adipocytes and protective for cardiovascular illnesses and diabetes mellitus (DM), was evaluated to clarify if drugs used in the therapy of these pathologies could influence in their effects. This evaluation was performed employing an animal model (normal mouse) and patients with Peripheral Vascular Disease (PVD) and/or Insulin-resistance (IR). Circulating levels of adiponectin, and factors related in the development and evolution of PVD and/or IR, were studied after the administration of drugs used in cardiovascular diseases (enalapril, telmisartan, metoprolol, amlodipine, isosorbide mononitrate, furosemide, acetil-salicilic-acid), dyslipidemia (simvastatin), and type 2 diabetes (rosiglitazone, metformin, glibenclamide). It was seen that adiponectin levels in females of the animal pattern, were significantly higher to those of males; similar data was confirmed in patients (women and men) with PVD and/or IR. When the glycerol release was studied in the animal model, we observed that basal lipolysis was more reduced in females than in males; however, females presented a greater forskolin induced lipolytic response. For drugs analysed, we have not find any correlation between antianginal effect and circulating levels of adiponectin, although telmisartan, rosiglitazone and glibenclamide showed a clear tendency to its increase. In contrast, metformin and simvastatin offered tendency to reduce this cytokine levels. In humans, the development of DM reduces adiponectinemia even more in both sexes; however, patients with PVD and DM2 using insulin glargine and/or lispro showed no variation on this cytokine serum levels. We confirm that the anti-ischemic drugs maintain the adiponectinemia, without relevant change, in both patients and normal mouse. In conclusion, although this cytokine can be a marker of diseases like the vascular ischemia and/or diabetes mellitus, it could not be an indicator of its favorable evolution following a specific treatment with broadly documented effectiveness.

[es] La adiponectina, citocina producida por adipocitos diferenciados y protectora ante enfermedades cardiovasculares y diabetes mellitus (DM), fue evaluada para esclarecer si los f?rmacos usados en la terapia de estas patolog?as, podr?an influir en sus efectos. En esta valoraci?n utilizamos un modelo animal (rat?n normal) y pacientes con Enfermedad Vascular Perif?rica (PVD) y/o Insulino-Resistencia (IR). Estudiamos la actividad sobre los niveles circulantes de adiponectina, y factores relacionados en el desarrollo y evoluci?n de PVD y/o IR, de algunos representantes de los grupos farmacol?gicos empleados en afecciones cardiovasculares (enalapril, telmisartan, metoprolol, amlodipino, mononitrato de isosorbide, furosemida, ?cido acetil-salic?lico), dislipidemias (simvastatina), e hipoglucemiantes orales (rosiglitazona, metformina, glibenclamida). Apreciamos que los niveles de adiponectina en hembras del modelo animal, son significativamente superiores a los de machos, aspecto igual a lo observado en pacientes (mujeres y hombres) con PVD y/o IR. Estudiando en el modelo animal la liberaci?n de glicerol, observamos que en situaci?n basal la lip?lisis estaba m?s reducida en hembras que en machos, aunque ellas presentaron mayor respuesta lipol?tica inducida por forskolina.Para los f?rmacos estudiados, no encontramos correlaci?n entre la eficacia antianginosa y los niveles circulantes de adiponectina, aunque telmisartan, rosiglitazona y glibenclamida mostraron clara tendencia a su incremento. En contraste, metformina y simvastatina ofrecieron tendencia reductora del nivel de esta citocina.En humanos, la instauraci?n de DM reduce a?n m?s la adiponectinemia en ambos sexos; sin embargo, los pacientes con PVD y DM2 tratados con insulina glargina y/o lispro mostraron efecto conservador de los niveles s?ricos de la citocina.Confirmamos que los f?rmacos antiisqu?micos no incrementan la adiponectinemia, tanto en cl?nica como en el rat?n normal.En conclusi?n, si bien esta citocina puede ser marcador de patolog?as como la isquemia vascular y/o la diabetes mellitus, no parece ser un indicador de su evoluci?n favorable bajo tratamiento espec?fico de eficacia ampliamente documentada.